BMB Reports 2023; 56(10): 545-550
Boeravinone B, a natural rotenoid, inhibits osteoclast differentiation through modulating NF-κB, MAPK and PI3K/Akt signaling pathways
Xianyu Piao1,2 , Jung-Woo Kim1,2 , Moonjung Hyun3, Zhao Wang1,2, Suk-Gyun Park1,2, In A Cho1,2, Je-Hwang Ryu1,2 , Bin-Na Lee4 , Ju Han Song1,2,* & Jeong-Tae Koh1,2,*
1Department of Pharmacology and Dental Therapeutics, School of Dentistry, Chonnam National University, Gwangju 61186, 2Hard-tissue Biointerface Research Center, School of Dentistry, Chonnam National University, Gwangju 61186, 3Gyeongnam Biohealth Research Center, Gyeongnam Branch Institute, Korea Institute of Toxicology, Jinju 52834, 4Department of Conservative Dentistry, School of Dentistry, Chonnam National University, Gwangju 61186, Korea
Correspondence to: Jeong-Tae Koh, Tel: +82-62-530-4861; Fax: +82-62-530-4807; E-mail:; Ju Han Song, Tel: +82-62-530-4860; Fax: +82-62-530-4807; E-mail:
Received: April 10, 2023; Revised: May 23, 2023; Accepted: August 12, 2023; Published online: August 29, 2023.
© Korean Society for Biochemistry and Molecular Biology. All rights reserved.

cc This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Osteoporosis is a major public health concern, which requires novel therapeutic strategies to prevent or mitigate bone loss. Natural compounds have attracted attention as potential therapeutic agents due to their safety and efficacy. In this study, we investigated the regulatory activities of boeravinone B (BOB), a natural rotenoid isolated from the medicinal plant Boerhavia diffusa, on the differentiation of osteoclasts and mesenchymal stem cells (MSCs), the two main cell components responsible for bone remodeling. We found that BOB inhibited osteoclast differentiation and function, as determined by TRAP staining and pit formation assay, with no significant cytotoxicity. Furthermore, our results showing that BOB ameliorates ovariectomy-induced bone loss demonstrated that BOB is also effective in vivo. BOB exerted its inhibitory effects on osteoclastogenesis by downregulating the RANKL/RANK signaling pathways, including NF-κB, MAPK, and PI3K/Akt, resulting in the suppression of osteoclast-specific gene expression. Further experiments revealed that, at least phenomenologically, BOB promotes osteoblast differentiation of bone marrow-derived MSCs but inhibits their differentiation into adipocytes. In conclusion, our study demonstrates that BOB inhibits osteoclastogenesis and promotes osteoblastogenesis in vitro by regulating various signaling pathways. These findings suggest that BOB has potential value as a novel therapeutic agent for the prevention and treatment of osteoporosis.
Keywords: Boeravinone B, Differentiation, Osteoclast, Osteoporosis, RANKL

Bone remodeling occurs throughout life to maintain mineral homeostasis through a tightly regulated process of bone resorption and formation. However, an imbalance between the two processes, such as excessive bone resorption or defective bone formation, can lead to bone mineral disorders such as osteoporosis (1). Owing to the serious health consequences and social costs associated with the increasing incidence of osteoporosis, continued efforts are needed to control this disease.

Hematopoietic stem cell-derived osteoclasts are the primary multinucleated cells responsible for bone resorption (2). The receptor activator of nuclear factor κB ligand (RANKL)/RANK pathway is the major signaling pathway involved in osteoclast differentiation and activation. The binding of RANKL to RANK on the surface of osteoclast progenitor cells activates downstream signaling pathways, including nuclear factor kappa B (NF-κB), mitogen-activated protein kinase (MAPK), and phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) pathways. Subsequently, these pathways induce the activation of transcription factors such as nuclear factor of activated T cells cytoplasmic 1 (NFATc1) and activator protein-1 (AP-1), which lead to the expression of effector molecules such as cathepsin K (CTSK) and tartrate-resistant acid phosphatase (TRAP) for osteoclastogenesis (3, 4). Therefore, the blockade of the signaling pathway induced by RANKL/RANK binding is considered a potential therapeutic target to inhibit osteoporosis (5-7).

Functionally opposite to osteoclasts in the continuous cycle of bone remodeling, osteoblasts are the primary cells responsible for bone formation by secreting organic substances essential for mineralization (8). Both osteoblasts and adipocytes are derived from MSCs; therefore, the balanced differentiation of MSCs into both cells in a reciprocal relationship plays an important role in maintaining bone homeostasis (9-11). Indeed, previous reports have shown that pathogenic conditions that cause bone loss, such as aging and menopause, coincide with increased adiposity in the bone marrow (12, 13). Therefore, enhancing the differentiation of MSCs into osteoblasts while inhibiting adipocyte differentiation represents a strategy to mitigate bone loss, in addition to inhibiting osteoclast differentiation or activity.

Natural compounds are considered promising therapeutics owing to their pharmacological effects and ability to provide long-term treatment with few side effects (5). Boeravinone B (BOB) is a natural rotenoid analog isolated from Boerhavia diffusa L., a medicinal plant used for gastrointestinal, hepatoprotective, and gynecological indications (14, 15). Recent studies have shown that BOB has inhibitory activities against inflammation, reactive oxygen species production, aging, cancer, and efflux pump (16-19). Given that BOB has been shown to have pharmacological activity, particularly in ameliorating metabolic disorders, we hypothesize that this phytochemical will have a beneficial effect on bone metabolism. Therefore, we investigated the regulatory activities of BOB in vitro and in vivo on bone remodeling. 


BOB inhibits osteoclast differentiation without cytotoxicity

First, we investigated the effect of BOB, whose chemical structure is shown in Fig. 1A, on osteoclast differentiation. Briefly, primary bone marrow macrophages (BMMs) were incubated with RANKL in the presence or absence of BOB at concentrations ranging from 5 to 40 μM. As a result, we observed a significant dose-dependent inhibition of RANKL-induced osteoclast formation, as determined by TRAP staining (Fig. 1B). The WST-8 cell viability assay showed that the concentrations of BOB used in this study did not significantly affect the survival of BMMs (Fig. 1C), thus excluding cytotoxicity as the cause of the BOB-mediated inhibition of osteoclastogenesis. These results suggest that BOB efficiently inhibits osteoclast differentiation without significant cytotoxicity.

BOB inhibits RANKL-induced osteoclast-specific gene expression

Next, we validated the efficacy of BOB in inhibiting osteoclast differentiation by altering the expression of osteoclast-specific markers. Western blot analysis showed that RANKL-mediated induction of NFATc1, a key transcription factor in osteoclastogenesis, was decreased by BOB in a dose-dependent manner (Fig. 2A). Similarly, in the presence of RANKL, the levels of both pro- and mature forms of CTSK, an osteoclast effector molecule, were reduced by BOB co-treatment (Fig. 2A). As shown in Fig. 2B and Supplementary Fig. 1, the mRNA levels of osteoclastogenesis-specific genes, such as Nfatc1, Trap, Ctsk, and Oscar, but not c-Fos, were also reduced by BOB in a dose-dependent manner. Furthermore, BOB inhibited RANKL-induced osteoclast differentiation in a time-dependent manner, which was validated by quantitative real-time PCR (qPCR) analysis of the osteoclast markers (Fig. 2C).

BOB inhibits osteoclast-mediated bone resorption in vitro and ovariectomy (OVX)-induced bone loss in vivo

Next, to further evaluate the effect of BOB on the resorbing activity of osteoclasts, we cultured BMMs with RANKL and BOB on a calcium phosphate coated plate. The results showed that treatment with BOB reduced pit formation of the calcium phosphate matrix by resorptive osteoclasts (Fig. 3A). As CTSK is a crucial protease secreted by activated osteoclasts, we next analyzed the changes in CTSK secretion in the culture supernatants obtained during the pit formation assay. The mature form of CTSK was detected in the RANKL-treated group but not in the group co-treated with BOB, as determined by western blot analysis (Fig. 3B). To further examine the anti-osteoporotic effect of BOB, we treated ovariectomized mice with BOB. The μ-CT results showed that OVX-induced bone loss in femur tended to be reduced by BOB administration (Fig. 3C); however, there was no significant weight loss in BOB-treated mice compared to ovariectomized mice receiving vehicle (Fig. 3D). Our data suggest that BOB can prevent OVX-induced bone loss without noteworthy toxicity.

BOB inhibits RANKL-induced activation of NF-κB and MAPK signaling pathways

We further investigated how BOB inhibits osteoclast differentiation by altering intracellular signaling pathways such as NF-κB, MAPK, and PI3K/Akt, which are activated by RANKL-RANK binding and play a critical role in the initiation of osteoclastogenesis. Western blot analysis showed that pretreatment with BOB suppressed RANKL-induced phosphorylation of Ikk, IκB, and p65, implying inhibition of the NF-κB signaling pathway (Fig. 4A). Consistent with these results, BOB strongly inhibited RANKL-mediated NF-κB translocation into the nucleus (Fig. 4B). We next examined the regulatory effect of BOB on RANKL-induced MAPK activation. Western blot analysis showed that BOB also reduced the phosphorylation of ERK and p38, but not JNK, among the three MAPKs (Fig. 4C). We further determined whether the BOB-induced decrease in NF-κB signaling was causally related to the decreased activity of two MAPKs, ERK and p38. As shown in Fig. 4D, pretreatment with either ERK (U0126) or p38 (SB202190) inhibitor did not significantly affect RANKL-induced p65 phosphorylation, indicating that BOB suppresses osteoclast differentiation by separately inhibiting the MAPK and NF-κB signaling pathways. Finally, we examined the effect of BOB on PI3K/Akt activation in osteoclastogenesis. Our results showed that the strong phosphorylation of PI3K and Akt exhibited in early osteoclastogenesis was greatly attenuated by pretreatment with BOB (Fig. 4E). These results demonstrate that BOB negatively regulates all three major early signaling pathways triggered by the interaction of RANKL and RANK, resulting in the inhibition of osteoclast differentiation.

BOB enhances osteoblast differentiation but inhibits adipocyte differentiation

Considering that bone homeostasis is regulated by bone resorption and bone formation, and that osteoblasts responsible for bone formation are derived from MSCs, we next investigated the effect of BOB on the multilineage differentiation of MSCs. In osteoblast differentiation of BMSCs, the addition of BOB promoted mineral deposition, as determined by ARS staining (Supplementary Fig. 2A). BOB also enhanced the expression of OPN and DMP1, markers for the late stage of osteoblast differentiation (Supplementary Fig. 2B). To verify the effect of BOB in promoting osteoblast differentiation, MC3T3-E1 cells were differentiated into osteoblasts in the presence of BOB. The results of ALP staining and Western blot analysis further confirmed that BOB promoted ALP activity and Runx2 expression in a concentration-dependent manner (Supplementary Fig. 2C, D).

During adipocyte differentiation of BMSCs, BOB inhibited the accumulation of intracellular lipid droplets with decreased expression of GLUT4 and AdipoQ (Supplementary Fig. 3A, B). To elucidate the mechanism by which BOB inhibits adipocyte differentiation, we examined its regulatory effect on the insulin signaling pathway. As shown in Supplementary Fig. 3C, pretreatment with BOB efficiently inhibited IRS-1 and Akt phosphorylation, both of which were increased by insulin stimulation. These results suggest that BOB can direct MSC commitment toward osteoblasts rather than adipocytes, thereby contributing to bone formation. 


Osteoporosis is a health issue that affects older people worldwide and is caused by free radicals and inflammatory mediators, which activate osteoclasts and decrease bone density (20). Plant-derived antioxidants are being studied as a means to control this condition (5, 21, 22). On this basis, we hypothesized that boeravinones may represent attractive candidates for the control of osteoporosis.

In the present study, we demonstrated that BOB, one of the boeravinones, inhibits the RANKL-RANK signaling pathway and attenuates three major signaling pathways induced by RANKL in BMMs, namely NF-κB, MAPK, and PI3K/Akt. This BOB activity inhibited osteoclast differentiation and reduced bone resorption activity, leading to an anti-osteoporotic effect. The findings suggest that boeravinones, particularly BOB, represents a promising candidate for the development of new anti-osteoporosis treatments.

Rotenoids, a class of isoflavonoid compounds found in medicinal plants belonging to the Lamiaceae family, have various pharmacological effects; however, only three specific compounds (rotenone, amorphigenin, and deguelin) have been identified as potential therapeutics for osteoporosis (23-25). Moreover, to best of our knowledge, the bone remodeling modulatory activity of boerhavinones (boerhavinones A to X), a class of rotenoids derived from Boerhaavia diffusa, has not yet been elucidated. Therefore, this study is the first to investigate the modulatory activity of boerhavinones in the pathophysiological research field. These compounds possess typical pharmacological activities of antioxidants including anti-inflammatory, antioxidant, anticancer, and anti-aging effects (26). As many antioxidants have demonstrated anti-osteoporotic effects, it is reasonable to speculate that boeravinones may also function as negative regulators of osteoclasts. Consequently, further investigation is needed to evaluate the efficacy of other boeravinones in inhibiting osteoclast differentiation and activity.

The three above-mentioned rotenoids have been shown to inhibit osteoclast differentiation by blocking RANKL activation of NF-κB and MAPK pathways (23-25). Our results showed that another rotenoid BOB can effectively inhibit both signaling pathways. Moreover, the inhibition of NF-κB activation by BOB was not the result of the inhibition of MAPK, as confirmed by studies using chemical inhibitors of ERK and p38. These results suggest that the TRAF6 complex, an upstream regulator of both pathways, is the direct target of BOB (4). However, further research is needed to confirm this hypothesis and to determine the precise target of BOB.

Akt, along with NF-κB and MAPK, is an important factor in the early stages of osteoclast differentiation; indeed, BMMs lacking Akt have been shown to exhibit defective osteoclast differentiation (27). Akt activation promotes the expression and nuclear translocation of NFATc1 through the inactivation of GSK-3β (28). Although previous studies have examined the effects of rotenoids on osteoclast differentiation, these have been limited to regulation of the NF-κB and MAPK pathways (23-25). This study extends research into the efficacy of BOB in context of Akt regulation. Interestingly, BOB at a concentration of 20 μM completely inhibited the PI3K/Akt signaling cascade induced by RANKL. BOB also showed similar inhibitory effects in Akt-mediated insulin signaling, which is critical for adipocyte differentiation. These results suggest that BOB improves bone mass by inhibiting the activation of the PI3K/Akt pathway, which contributes to osteoclast and adipocyte differentiation.

In addition to inhibiting osteoclast differentiation and activity, enhancement of osteoblast differentiation is another strategy for the treatment of osteoporosis. MSCs are multipotent cells that can differentiate into osteoblasts and adipocytes. An imbalance between the two cell lineages in the bone marrow, i.e., a decrease in osteoblasts and an excessive increase in adipocytes, has been reported to be associated with increased bone fragility (12, 13). In this study, the effects of BOB on osteoblast and adipocyte differentiation were examined using BMSCs, where the addition of BOB to BMSCs was shown to promote matrix mineralization. Although we have not performed sufficient in-depth studies to explain this enhancement, the result suggests that BOB is involved in the functional maturation of osteoblasts to induce mineral deposition. However, BOB also had a significant inhibitory effect on the in vitro adipogenic differentiation of BMSCs, as evidenced by the analysis of lipid droplet accumulation, marker expression, and insulin signaling. These results suggest that BOB contributes to the maintenance of bone marrow homeostasis by preventing MSCs from transforming and accumulating into adipocytes. As the commitment of MSCs to both lineages is regulated by crosstalk between key transcription factors, such as Runx2 and PPARγ (29), the effect of BOB on the activity of transcription factors remains to be elucidated in further studies.

In conclusion, BOB can to comprehensively control the differentiation of cells responsible for bone remodeling, at least in an in vitro system. Our findings provide evidence to support BOB as a potential therapeutic agent for bone diseases. 



BOB was purchased from PhytoLab and dissolved in DMSO. Recombinant mouse M-CSF and RANKL were obtained from Biolegend and Peprotech, respectively. Antibodies used in this study are described in Supplementary Material.

Cell culture and osteoclast differentiation

BMMs were isolated from C57BL/6 mouse bone marrow cells and cultured in α-MEM medium (Gibco) supplemented with 10% fetal bovine serum (Gibco) and 1% penicillin and streptomycin (Gibco), as previously described (30). To induce osteoclast differentiation, BMMs were seeded at a density of 5 × 105/ml and incubated for 3 to 4 days in the medium containing 30 ng/ml M-CSF and 100 ng/ml RANKL.

TRAP staining

Osteoclast differentiation was assessed using a TRAP staining kit (Cosmo Bio), according to the manufacturer’s instructions. Images were acquired using a Lionheart FX Cell Imager (BioTek). TRAP-positive multinucleated cells with three or more nuclei were counted as osteoclasts.

qPCR analysis

Total RNA was extracted from cell samples using TRIzol reagent (Ambion). Two micrograms of total RNA were reverse-transcribed into cDNA using M-MLV reverse transcriptase (Promega). Transcriptional levels of marker genes in the cDNA samples were assessed using a QuantStudio cycler (Applied Biosystem) with Power SYBR Green PCR Master Mix (Applied Biosystem) and the primer sets described in Supplementary Material. Data are presented as the relative expression of the ΔΔCt value obtained using QuantStudio Design & Analysis software (Applied Biosystem), with 18S rRNA used as an internal control.

Western blot analysis

Whole cell lysates were prepared using Cell Lysis Buffer (Cell Signaling Technology). Specifically, cytoplasmic and nuclear cell fractions were extracted using the NE-PER Nuclear and Cytoplasmic Extraction Reagent Kit (Thermo Fisher Scientific) according to the manufacturer’s protocol. For western blot analysis, equal amounts of proteins were electrophoresed on an SDS-PAGE gel and transferred to a PVDF membrane. The membranes were blocked in blocking buffer (tris-buffered saline with 0.1% Tween-20 and 5% nonfat milk) and then incubated with primary antibodies and HRP-conjugated secondary antibodies. Immunobands were detected with ECL solution (Millipore).

OVX-induced bone loss mouse model

The animal study was conducted according to the guidelines of the Institutional Animal Care and Use Committees of Chonnam National University. Eight-week-old C57BL/6 mice were anesthetized, and a midline abdominal skin incision was made. Bilateral ovaries were excised and both ends were closed by suturing. Sham-operated mice underwent the same procedure without removal of the ovaries. All mice were allowed 1 week of recovery with the intraperitoneal administration of gentamicin (50 mg/kg) to prevent infection. After an additional 3 weeks of rest to induce bone loss, mice were randomly divided into four groups (n = 4/group) and then injected intraperitoneally every other day with either PBS containing vehicle (1% DMSO) or BOB (5 mg/kg and 20 mg/kg) for 4 weeks. The mice were sacrificed, and their femurs were fixed in formalin. Bone analysis by μ-CT scanning was performed as described in Supplementary Material.

Statistical analysis

Results were obtained from at least two independent experiments. Student’s t test was used to determine the statistical significance of the data. A P-value < 0.05 was considered statistically significant. 


We thank Sin-Hye Oh and Seung Hee Kwon for their technical assistance. This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (No. 2019R1A5A2027521); the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (No. NRF-2020R1I1A1A01061824); the Korean Fund for Regenerative Medicine (KFRM) grant (Ministry of Science and ICT, Ministry of Health & Welfare, 22A0104L1); and by the National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIT) (NRF-2021R1C1C2009626).


The authors have no conflicting interests.

Fig. 1. BOB inhibits RANKL-induced osteoclast differentiation without cytotoxicity. (A) Chemical structure of BOB. (B) BMMs were incubated with RANKL for 4 days in the presence or absence of BOB (5-40 μM) and stained with the TRAP staining kit. Representative images and quantification of TRAP formation from three independent experiments are shown. Scale bar: 500 μm. *P-value vs. untreated control. (C) BMMs were cultured in the presence of BOB for 3 days, before assessing their viability by WST-8 assay. Data are expressed as relative values compared to the viability of the untreated control.
Fig. 2. BOB inhibits RANKL-induced osteoclast marker expression. (A, B) BMMs were treated with the indicated reagents for 3 days. Protein lysates and mRNA were used for western blot (A) and qPCR analysis (B). For western blot analysis, β-actin was used as the loading control. A representative blot of two independent experiments is shown. *P-value vs. RANKL-treated cells. (C) Relative mRNA expression was determined in cultures treated with RANKL and BOB (20 μM) at the indicated time points. *P-value vs. RANKL-treated cells at the same time points.
Fig. 3. BOB inhibits osteoclast resorption activity in vitro and bone loss in vivo. (A) Representative images of pit formation are shown, and the percentage of pit area per field was quantified. n = 4 wells/group. Scale bar: 100 μm. *P-value vs. RANKL-treated well. (B) Soluble CTSK in the supernatants was detected by western blot analysis. The membrane stained with Ponceau S is shown to demonstrate equal loading. (C) Representative images and bone parameters of femoral trabecular bone are shown. #P-value vs. sham-vehicle, *P-value vs. OVX-vehicle. (D) Changes in body weight are presented as a percentage compared to the body weight of each untreated group.
Fig. 4. BOB inhibits RANKL-induced activation of the NF-κB, MAPK, and PI3K/Akt signaling pathways. BMMs were pretreated with either BOB (20 μM) or specific inhibitors for 30 min prior to RANKL treatment and harvested at the indicated time points. (A) NF-κB pathway was assessed by Western blot analysis. (B) Nuclear translocation of NF-κB p65 in the cells were examined by western blotting. MEK2 and lamin B were used as markers for the cytoplasmic and nuclear fractions, respectively. (C) Phosphorylation of the MAPKs was examined by western blotting. (D) Effect of either U0126 (ERKinhi) or SB202190 (p38inhi) in the activation of NF-κB p65 was examined by western blotting. (E) Phosphorylation of PI3K and Akt was determined by western blotting. β-actin was used as the loading control.
  1. Liang B, Burley G, Lin S and Shi YC (2022) Osteoporosis pathogenesis and treatment: existing and emerging avenues. Cell Mol Biol Lett 27, 72.
    Pubmed KoreaMed CrossRef
  2. Elson A, Anuj A, Barnea-Zohar M and Reuven N (2022) The origins and formation of bone-resorbing osteoclasts. Bone 164, 116538.
    Pubmed CrossRef
  3. Kim JH and Kim N (2014) Regulation of NFATc1 in osteoclast differentiation. J Bone Metab 21, 233-241.
    Pubmed KoreaMed CrossRef
  4. Park JH, Lee NK and Lee SY (2017) Current understanding of RANK signaling in osteoclast differentiation and maturation. Mol Cells 40, 706-713.
  5. An J, Hao D and Zhang Q et al (2016) Natural products for treatment of bone erosive diseases: the effects and mechanisms on inhibiting osteoclastogenesis and bone resorption. Int Immunopharmacol 36, 118-131.
    Pubmed CrossRef
  6. Chen X, Zhi X and Pan P et al (2017) Matrine prevents bone loss in ovariectomized mice by inhibiting RANKL-induced osteoclastogenesis. FASEB J 31, 4855-4865.
    KoreaMed CrossRef
  7. Kang JH, Lim H, Jeong JE and Yim M (2016) Attenuation of RANKL-induced osteoclast formation via p38-mediated NFATc1 signaling pathways by extract of Euphorbia Lathyris L. J Bone Metab 23, 207-214.
    Pubmed KoreaMed CrossRef
  8. Raggatt LJ and Partridge NC (2010) Cellular and molecular mechanisms of bone remodeling. J Biol Chem 285, 25103-25108.
    Pubmed KoreaMed CrossRef
  9. Akune T, Ohba S and Kamekura S et al (2004) PPARgamma insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. J Clin Invest 113, 846-855.
    Pubmed KoreaMed CrossRef
  10. Han Y, Kim CY, Cheong H and Lee KY (2016) Osterix represses adipogenesis by negatively regulating PPARγ transcriptional activity. Sci Rep 6, 35655.
    Pubmed KoreaMed CrossRef
  11. Tosa I, Yamada D and Yasumatsu M et al (2019) Postnatal Runx2 deletion leads to low bone mass and adipocyte accumulation in mice bone tissues. Biochem Biophys Res Commun 516, 1229-1233.
  12. Chandra A, Lagnado AB and Farr JN et al (2022) Bone marrow adiposity in models of radiation- and aging-related bone loss is dependent on cellular senescence. J Bone Miner Res 37, 997-1011.
    Pubmed KoreaMed CrossRef
  13. Li J, Chen X, Lu L and Yu X (2020) The relationship between bone marrow adipose tissue and bone metabolism in postmenopausal osteoporosis. Cytokine Growth Factor Rev 52, 88-98.
    Pubmed CrossRef
  14. Bairwa K, Singh IN, Roy SK, Grover J, ivastava A Sr and Jachak SM (2013) Rotenoids from Boerhaavia diffusa as potential anti-inflammatory agents. J Nat Prod 76, 1393-1398.
    Pubmed CrossRef
  15. Mishra S, Aeri V, Gaur PK and Jachak SM (2014) Phytochemical, therapeutic, and ethnopharmacological overview for a traditionally important herb: Boerhavia diffusa Linn. Biomed Res Int 2014, 808302.
    Pubmed KoreaMed CrossRef
  16. Biradar SP, Tamboli AS, Khandare RV and Pawar PK (2019) Chebulinic acid and Boeravinone B act as anti-aging and anti-apoptosis phyto-molecules during oxidative stress. Mitochondrion 46, 236-246.
    Pubmed CrossRef
  17. Huang Y, Sun Y, Wang WW and Zhang L (2018) Boeravinone B a natural rotenoid exerts anticancer activity via inducing internalization and degradation of inactivated EGFR and ErbB2 in human colon cancer cells. Am J Transl Res 10, 4183-4192.
  18. Singh S, Kalia NP and Joshi P et al (2017) Boeravinone B, a novel dual inhibitor of NorA bacterial efflux pump of Staphylococcus aureus and human P-glycoprotein, reduces the biofilm formation and intracellular invasion of bacteria. Front Microbiol 8, 1868.
    Pubmed KoreaMed CrossRef
  19. Yuan S and Zhang T (2021) Boeravinone B protects brain against cerebral ichemia reperfusion injury in rats: possible role of anti-inflammatory and antioxidant. J Oleo Sci 70, 927-936.
    Pubmed CrossRef
  20. Armour KJ, Armour KE and van't Hof RJ et al (2001) Activation of the inducible nitric oxide synthase pathway contributes to inflammation-induced osteoporosis by suppressing bone formation and causing osteoblast apoptosis. Arthritis Rheum 44, 2790-2796.
    Pubmed CrossRef
  21. Jayusman PA, Nasruddin NS, Baharin B, Ibrahim N', Ahmad Hairi H and Shuid AN (2023) Overview on postmenopausal osteoporosis and periodontitis: the therapeutic potential of phytoestrogens against alveolar bone loss. Front Pharmacol 14, 1120457.
    Pubmed KoreaMed CrossRef
  22. Xu Q, Cao Z and Xu J et al (2022) Effects and mechanisms of natural plant active compounds for the treatment of osteoclast-mediated bone destructive diseases. J Drug Target 30, 394-412.
  23. Kwak HB, Lee BK and Oh J et al (2010) Inhibition of osteoclast differentiation and bone resorption by rotenone, through down-regulation of RANKL-induced c-Fos and NFATc1 expression. Bone 46, 724-731.
    Pubmed CrossRef
  24. Kim BG, Kwak HB and Choi EY et al (2010) Amorphigenin inhibits osteoclast differentiation by suppressing c-Fos and nuclear factor of activated T cells. Anat Cell Biol 43, 310-316.
    Pubmed KoreaMed CrossRef
  25. Zhang T, Zhao K and Han W et al (2019) Deguelin inhibits RANKL-induced osteoclastogenesis in vitro and prevents inflammation-mediated bone loss in vivo. J Cell Physiol 234, 2719-2729.
    Pubmed CrossRef
  26. Praveen Kumar PK, Priyadharshini A and Muthukumaran S (2021) A review on rotenoids: purification, characterization and its biological applications. Mini Rev Med Chem 21, 1734-1746.
    Pubmed CrossRef
  27. Sugatani T and Hruska KA (2005) Akt1/Akt2 and mammalian target of rapamycin/Bim play critical roles in osteoclast differentiation and survival, respectively, whereas Akt is dispensable for cell survival in isolated osteoclast precursors. J Biol Chem 280, 3583-3589.
    Pubmed CrossRef
  28. Moon JB, Kim JH and Kim K et al (2012) Akt induces osteoclast differentiation through regulating the GSK3β/NFATc1 signaling cascade. J Immunol 188, 163-169.
    Pubmed CrossRef
  29. Chen Q, Shou P and Zheng C et al (2016) Fate decision of mesenchymal stem cells: adipocytes or osteoblasts?. Cell Death Differ 23, 1128-1139.
    Pubmed CrossRef
  30. Zang Y, Song JH and Oh SH et al (2020) Targeting NLRP3 inflammasome reduces age-related experimental alveolar bone loss. J Dent Res 99, 1287-1295.

This Article

Cited By Articles
  • CrossRef (0)

Author ORCID Information

Funding Information


Social Network Service